Travere Therapeutics grants inducement equity awards covering 178,580 shares to 33 new hires

By Public Technologies
  • Travere Therapeutics reported inducement equity awards covering 178,580 shares for 33 new employees, granted on Oct. 10, 2026.
  • Awards included stock options for 36,000 shares, structured as non-qualified options with a 10-year term.
  • Options vest over four years, with 25% vesting after one year, then monthly vesting over the next 36 months.
  • Restricted stock units covered 142,580 shares, vesting over four years in 25% annual installments.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610121700BIZWIRE_USPR_____20261012_BW301172) on October 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.